scholarly journals Serum Adiponectin Levels in Advanced-Stage Parkinson's Disease Patients

2011 ◽  
Vol 2011 ◽  
pp. 1-6
Author(s):  
Erica Cassani ◽  
Raffaella Cancello ◽  
Ferruccio Cavanna ◽  
Sabrina Maestrini ◽  
Anna Maria Di Blasio ◽  
...  
Keyword(s):  
Parkinson’S Disease ◽  
Parkinson's Disease ◽  
Cardiovascular Risk ◽  
Body Weight Loss ◽  
Serum Levels ◽  
Normal Weight ◽  
Morbidly Obese ◽  
Serum Concentrations ◽  
Status Assessment ◽  
Young Subjects

Patients with advanced Parkinson's disease (PD) experience body weight loss and reductions in the most common cardiovascular risk factors. At present, the pathogenetic mechanisms involved have not been elucidated. Increased serum concentrations of adiponectin, which possesses antiatherogenic and anti-inflammatory properties, are associated with a reduction in cardiovascular risk. The objective of this study was to determine adiponectin serum concentrations in PD patients. Thirty PD patients underwent a full nutritional status assessment, including the determination of adiponectin serum concentrations. Mean ± SD adiponectin concentrations were 9.59 ± 5.9 μg/mL (interquartile range: 5.92–12.9 μg/mL). In PD patients, adiponectin serum levels were similar to those in normal-weight, healthy, young subjects and significantly higher than that in an aged-matched group of morbidly obese subjects. Further studies are warranted to establish the role of adiponectin in the management of PD patients.

scholarly journals Restless legs syndrome in Parkinson's disease and increased cardiovascular risk

2018 ◽  
Vol 76 (11) ◽  
pp. 731-735 ◽  
Author(s):  
Maren de Moraes e Silva ◽  
Cezar Henrique Lorenzi ◽  
Blenda Barreto Schneider ◽  
Catherine Enk Fischer Seidel ◽  
Isabela Salomé ◽  
...  
Keyword(s):  
Parkinson’S Disease ◽  
Parkinson's Disease ◽  
Cardiovascular Risk ◽  
Restless Legs Syndrome ◽  
Protective Factor ◽  
Risk Scores ◽  
Dopaminergic Transmission ◽  
Restless Legs ◽  
Cardiovascular Comorbidities ◽  
Framingham Risk

ABSTRACT Restless legs syndrome (RLS) is a disorder commonly found in patients with Parkinson's disease, with descriptions for both conditions impairing dopaminergic transmission in central nervous system. Previous studies in varied populations indicate an association between the presence of RLS and increased cardiovascular risk and, so far, there are no consistent studies of this association in Parkinson's disease. Objective: To analyze the influence of RLS on cardiovascular risk in patients with Parkinson's disease. Methods: We reviewed the medical records of 202 patients diagnosed with Parkinson's disease and verified the presence of RLS, cardiovascular comorbidities, blood pressure measurements, lipid profiles and Framingham Risk Scores. Results: Statistically significant higher values of total cholesterol were found for the RLS group (mean 216.6 mg/dL), as well as for LDL cholesterol (mean 145 mg/dL). No statistical difference was found among the other factors. Conclusion: Patients with Parkinson's disease and RLS have a higher prevalence of dyslipidemia than patients without RLS, suggesting a correlation between restless legs and hyperlipidemia. It is questioned whether the dopaminergic substrate is the main factor in the genesis of the syndrome, as even with the use of dopaminergic agonists by both groups, it was possible to observe differences between groups. The hypothesis of the real interference of the syndrome treatment as a protective factor for cardiovascular risk was generated.

Higher serum levels of pro-hepcidin in patients with Parkinson’s disease treated with deep brain stimulation

2018 ◽  
Vol 684 ◽  
pp. 205-209 ◽  
Author(s):  
J. Kwiatek-Majkusiak ◽  
M. Geremek ◽  
D. Koziorowski ◽  
R. Tomasiuk ◽  
S. Szlufik ◽  
...  
Keyword(s):  
Parkinson’S Disease ◽  
Parkinson's Disease ◽  
Deep Brain Stimulation ◽  
Brain Stimulation ◽  
Serum Levels ◽  
Deep Brain

Cardiovascular Risk Among Patients ≥65 Years of Age with Parkinson's Disease (From the National Inpatient Sample)

2020 ◽  
Vol 136 ◽  
pp. 56-61 ◽  
Author(s):  
Ashraf Abugroun ◽  
Ahmed Taha ◽  
Manar Abdel-Rahman ◽  
Pragnesh Patel ◽  
Ibtisam Ali ◽  
...  
Keyword(s):  
Parkinson’S Disease ◽  
Parkinson's Disease ◽  
Cardiovascular Risk ◽  
National Inpatient Sample

scholarly journals The effects of motor rehabilitation training on clinical symptoms and serum BDNF levels in Parkinson’s disease subjects

2016 ◽  
Vol 94 (4) ◽  
pp. 455-461 ◽  
Author(s):  
Francesco Angelucci ◽  
Jacopo Piermaria ◽  
Francesca Gelfo ◽  
Jacob Shofany ◽  
Marco Tramontano ◽  
...  
Keyword(s):  
Parkinson’S Disease ◽  
Parkinson's Disease ◽  
Clinical Symptoms ◽  
Serum Levels ◽  
Motor Rehabilitation ◽  
Walking Test ◽  
Rehabilitation Training ◽  
Extrapyramidal Signs ◽  
Serum Bdnf

Increasing evidence suggests that motor rehabilitation may delay Parkinson’s disease (PD) progression. Moreover, parallel treatments in animals up-regulate brain-derived neurotrophic factor (BDNF). Thus, we investigated the effect of a motor rehabilitation protocol on PD symptoms and BDNF serum levels. Motor rehabilitation training consisted of a cycle of 20 days/month of physiotherapy divided in 3 daily sessions. Clinical data were collected at the beginning, at the end, and at 90 days follow-up. BDNF serum levels were detected by ELISA at 0, 7, 14, 21, 30, and 90 days. The follow-up period had a duration of 60 days (T30–T90). The results showed that at the end of the treatment (day 30), an improvement in extrapyramidal signs (UPDRS III; UPDRS III – Gait and Balance items), motor (6 Minute Walking Test), and daily living activities (UPDRS II; PDQ-39) was observed. BDNF levels were increased at day 7 as compared with baseline. After that, no changes in BDNF were observed during the treatment and in the successive follow-up. This study demonstrates that motor rehabilitation training is able to ameliorate PD symptoms and to increase temporarily BDNF serum levels. The latter effect may potentially contribute to the therapeutic action.

Homocysteine serum levels and MTHFR C677T genotype in patients with Parkinson's disease, with and without levodopa therapy

2006 ◽  
Vol 248 (1-2) ◽  
pp. 56-61 ◽  
Author(s):  
Zoran Todorović ◽  
Eleonora Džoljić ◽  
Ivana Novaković ◽  
Duško Mirković ◽  
Radan Stojanović ◽  
...  
Keyword(s):  
Parkinson’S Disease ◽  
Parkinson's Disease ◽  
Mthfr C677t ◽  
Serum Levels ◽  
Levodopa Therapy

scholarly journals Abnormal serum concentrations of proteins in Parkinson’s disease

2009 ◽  
Vol 389 (2) ◽  
pp. 321-327 ◽  
Author(s):  
Ira L. Goldknopf ◽  
Jennifer K. Bryson ◽  
Irina Strelets ◽  
Silvia Quintero ◽  
Essam A. Sheta ◽  
...  
Keyword(s):  
Parkinson’S Disease ◽  
Parkinson's Disease ◽  
Serum Concentrations
Sign in / Sign up

Export Citation Format

Share Document